Samanthi A. Perera

Takeda (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

20h-index5.4kcitations123works0.12yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Heat shock proteins research(42), Cancer Immunotherapy and Biomarkers(30), ATP Synthase and ATPases Research(23), Cytokine Signaling Pathways and Interactions(22), interferon and immune responses(18)

Publications123 total

Table 2 from Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors

2025Open Access

Supplemental Methods from Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors

2025Open Access

Supplemental Figure S1 from Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors

2025Open Access

Table 4 from Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors

2025Open Access

Supplemental Figure S4 from Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors

2025Open Access

Figure 3 from Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors

2025Open Access

Figure 1 from Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors

2025Open Access

Supplemental Table S3 from Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors

2025Open Access

Supplemental Table S2 from Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors

2025Open Access

Supplemental Table S4 from Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors

2025Open Access

Figure 2 from Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors

2025Open Access

Supplemental Figure S3 from Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors

2025Open Access

Supplemental Table S5 from Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors

2025Open Access

Data from Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors

2025Open Access

Supplemental Table S1 from Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors

2025Open Access

Supplemental Figure S2 from Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors

2025Open Access

Supplemental Table S7 from Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors

2025Open Access

Table 3 from Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors

2025Open Access

Supplemental Table S6 from Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors

2025Open Access

Table 1 from Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors

2025Open Access

page 1 of 7Next →

Frequent Co-authors

Kwok‐Kin Wong(28), Robert F. Padera(18), Danan Li(18), Kate McNamara(15), Takeshi Shimamura(15), Geoffrey I. Shapiro(15), Sara Zaghlul(15), Liang Chen(14), Lucian R. Chirieac(14), Matthew Meyerson(14), Hongbin Ji(13), Christa L. Borgman(13), Roman K. Thomas(12), Brian J. Long(9), Roderick T. Bronson(8), Johnny E. Kopinja(8), Shigeto Kubo(8), Masaya Takahashi(8), Julián Carretero(8), Bo‐Sheng Pan(7)